Article Title: “AI legislation seen as unlikely to pass anytime soon”
Publication Date: December 4, 2025
As discussed at the Food and Drug Law Institute’s enforcement conference on December 4, 2025, the topic of AI legislation for FDA compliance activities was unveiled. However, industry veteran Nathan Brown of Akin Gump expressed skepticism, suggesting the detailed complexities of such legislation make the likelihood of it passing federally any time soon exceedingly slim.
AI holds much promise for streamlining compliance with FDA regulations. However, managing the intricacies of legislation in this space is challenging. The decision-making algorithms that power AI are not always transparent, and the rate of change in the technology itself makes it difficult to keep regulatory measures up-to-date. Therefore, it is not surprising that AI legislation faces hurdles in gaining sufficient consensus for enactment in the near term.
Nathan Brown’s concerns about the manageability of such a detailed legislation highlight the ongoing conundrum facing companies pioneering in the AI space. The uncertainty hovering around this subject poses potential risks to businesses investing heavily in AI to automate FDA compliance processes, as they may find themselves dealing with an unstable regulatory landscape.
In terms of market impact, the delay in AI legislation might slow down innovation in areas where AI could be used to simplify FDA compliance procedures. This delay could present an opportunity for firms offering manual compliance services to maintain their market position, while AI-centric firms might face a slowing growth trajectory in the short term.
In light of these developments, the road to AI legislation appears laden with challenges that might decelerate the adoption and evolution of AI in FDA compliance space, at least in the near future. As always, Industry Informant remains at the forefront, dedicated to keeping industry decision-makers and investors informed of such key market dynamics and legislative developments.
